Charles River Laboratories International, Inc.

NYSE:CRL Stock Report

Market Cap: US$13.8b

Charles River Laboratories International Dividend

Dividend criteria checks 0/6

Charles River Laboratories International does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield0.4%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$9.24
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Feb 21
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'

Feb 16

Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Jan 17
Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Jan 02
Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Dec 17
Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation

Nov 26

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Nov 12
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Charles River: Q3 Points To Ongoing Deterioration

Nov 09

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 27
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Oct 12
At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Charles River Laboratories: Diving Into The Lab (Rating Upgrade)

Oct 06

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Aug 10
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Charles River Laboratories: Very Attractive After The Pullback

Jul 26

Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Jul 22
Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

Jul 03
Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

Jun 19
When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)

May 01
A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)

Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?

Apr 16
Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?

These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well

Apr 02
These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well

Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Mar 19
Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Charles River gains as Guggenheim upgrades despite post-earnings selloff

Feb 23

Charles River Laboratories International: A Great Business At A Decent Price

Feb 06

Charles River acquires SAMDI Tech for $50M in cash

Jan 30

Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?

Jan 24
Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?

If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity

Jan 10
If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity

Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital

Jan 05

We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt

Dec 28
We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt

Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Dec 14
Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance

Nov 02

Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds

Oct 18

Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?

Oct 18
Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?

Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Oct 04
Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Charles River raised to Buy at Jefferies on prospects for animal studies

Sep 30

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Sep 21
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories: A 'Picks And Shovels' Biomedical Play, Now Attractively Priced

Sep 10

Is Now The Time To Look At Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Sep 07
Is Now The Time To Look At Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories hits new 52-week low; shares down 43% YTD

Aug 30

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CRL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRL's dividend payments have been increasing.


Dividend Yield vs Market

Charles River Laboratories International Dividend Yield vs Market
How does CRL dividend yield compare to the market?
SegmentDividend Yield
Company (CRL)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Life Sciences)0.4%
Analyst forecast in 3 Years (CRL)0%

Notable Dividend: Unable to evaluate CRL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CRL's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRL has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.